Literature DB >> 2993433

Human monoclonal antibodies neutralizing varicella-zoster virus.

S K Foung, S Perkins, C Koropchak, D M Fishwild, A E Wittek, E G Engleman, F C Grumet, A M Arvin.   

Abstract

Hybridomas secreting human monoclonal antibodies to varicella-zoster virus were produced by fusing B cells of a patient recovering from acute varicella infection with a human-mouse cell line. Two hybrid lines have continued to secrete IgG1, one with kappa and the other with lambda chains, for at least 12 months. Each antibody neutralizes virus infectivity between 1-5 micrograms of partially purified immunoglobulin/ml, each shows a different pattern of immunofluorescent staining of virus-infected cells, and one identifies three viral proteins with molecular weights of 60,000, 95,000, and 97,000.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2993433     DOI: 10.1093/infdis/152.2.280

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  5 in total

1.  Neutralizing human monoclonal antibodies to conformational epitopes of human T-cell lymphotropic virus type 1 and 2 gp46.

Authors:  K G Hadlock; J Rowe; S Perkins; P Bradshaw; G Y Song; C Cheng; J Yang; R Gascon; J Halmos; S M Rehman; M S McGrath; S K Foung
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 2.  New and old aspects of immunoglobulin application. The use of intravenous IgG as prophylaxis and for treatment of infections.

Authors:  L Hammarström; C I Smith
Journal:  Infection       Date:  1990 Sep-Oct       Impact factor: 3.553

3.  Human anti-varicella-zoster virus (VZV) recombinant monoclonal antibody produced after Zostavax immunization recognizes the gH/gL complex and neutralizes VZV infection.

Authors:  Marius Birlea; Gregory P Owens; Emily M Eshleman; Alanna Ritchie; Igor Traktinskiy; Nathan Bos; Scott Seitz; Yevgeniy Azarkh; Ravi Mahalingam; Don Gilden; Randall J Cohrs
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

4.  Chickenpox pneumonia: experience with antiviral treatment.

Authors:  R N Davidson; W Lynn; P Savage; M H Wansbrough-Jones
Journal:  Thorax       Date:  1988-08       Impact factor: 9.139

Review 5.  Exploring the native human antibody repertoire to create antiviral therapeutics.

Authors:  S K Dessain; S P Adekar; J D Berry
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.